Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04043923 · ClinicalTrials.gov registry record · Phase 2
Norketotifen for the Treatment of Uncomplicated Influenza-like Illness
A Phase 2 study, sponsored by Emergo Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 238
- Enrollment target
NCT04043923: Completed Phase 2 study, sponsored by Emergo Therapeutics.
NCT04043923 is a Phase 2 study that has completed, run by Emergo Therapeutics. The registered enrollment target is 238 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04043923, a Phase 2 study, has completed, sponsored by Emergo Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 238 participants
- Enrollment target
Study Summary
This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.
Primary Outcome
Time to alleviation of the symptoms of ILI (headache, feverishness/chills, muscle/joint pain, fatigue, cough, sore throat, nasal congestion)
Interventions
- DRUG Placebo
- DRUG Norketotifen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 238 participants |
| Start Date | 2019-10-21 |
| Est. Completion | 2020-04-20 |
| Phase | Phase 2 |
What the finished NCT04043923 record still lists
NCT04043923 is an interventional study that assigns participants to a tested intervention. The registered 238 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (79% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04043923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04043923 about?
NCT04043923 is a clinical study titled "Norketotifen for the Treatment of Uncomplicated Influenza-like Illness". This is a Phase 2b, multi-center, double-blind, randomized, placebo-controlled, parallel-group study of NKT versus placebo in otherwise healthy adults presenting with acute uncomplicated ILI due to influenza or other respiratory viruses in a community setting.
What is the current status of trial NCT04043923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 238 participants. The study started on 2019-10-21. Estimated completion is 2020-04-20.
What interventions are being tested in trial NCT04043923?
The interventions under investigation include: Placebo (DRUG), Norketotifen (DRUG).
Who is sponsoring clinical trial NCT04043923?
This trial is sponsored by Emergo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04043923's enrollment target sits among peer trials
238 255th of 2000 higher than 1,746 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
- NCT06452797 · 238 participants · NA
Prognostic Estimates Among ICU Clinicians
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI